Bristol Myers Squibb announced results from three updated analyses from the CheckMate-77T, CheckMate-816, and CheckMate-9LA studies supporting Opdivo (nivolumab) and Opdivo-based combinations in early stage and advanced non-small cell lung cancer. Data were presented at the 2024 American Society of Clinical Oncology Annual Meeting.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe